Edition:
United States

Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

124.70EUR
11:15am EDT
Change (% chg)

€0.50 (+0.40%)
Prev Close
€124.20
Open
€124.15
Day's High
€125.00
Day's Low
€123.80
Volume
14,614
Avg. Vol
37,633
52-wk High
€130.00
52-wk Low
€93.10

BIOX.PA

Chart for BIOX.PA

About

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial... (more)

Overall

Beta: 0.37
Market Cap(Mil.): €4,900.15
Shares Outstanding(Mil.): 39.45
Dividend: 1.00
Yield (%): 0.81

Financials

  BIOX.PA Industry Sector
P/E (TTM): 44.34 43.41 37.71
EPS (TTM): 2.80 -- --
ROI: 5.48 11.61 14.43
ROE: 7.69 13.65 15.61

BRIEF-Biomerieux H1 sales up 10.9 pct, at constant exchange rates and scope of consolidation

* Strong growth in sales, up 10.9 pct, at constant exchange rates and scope of consolidation in first half of 2016

Jul 18 2016

BRIEF-Biomerieux reports Q2 growth in sales of 10.9 pct

* Q2 strong growth in sales, up 10.9 pct, at constant exchange rates and scope of consolidation in first half of 2016

Jul 18 2016

BRIEF-Biomerieux gets FDA clearance for VIDAS B.R.A.H.M.S PCT test

* Biomerieux receives FDA clearance for expanded use of VIDAS B.R.A.H.M.S PCT test for managing sepsis patients with elevated risk of mortality Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 01 2016

French and Benelux stocks-Factors to watch on June 1

PARIS, June 1 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.

Jun 01 2016

BRIEF-Biomerieux and Lyon Civil Hospitals expand their partnership

* Said on Tuesday Biomerieux and the Lyon Civil Hospitals strengthen their collaboration and expand their partnership to include Claude Bernard University Lyon 1 Source text: http://bit.ly/1UcS73f Further company coverage: (Gdynia Newsroom:)

Jun 01 2016

BRIEF-Biomerieux acquires Hyglos

* Biomérieux acquires Hyglos and expands its offering to the detection of endotoxins in pharmaceutical products

Jun 01 2016

BRIEF-Biomerieux Q1 sales 489 million euros, up 9.1 percent

* Reported on Wednessday Q1 sales 489 million euros ($552.18 million), up 9.1 percent

Apr 21 2016

BRIEF-Biomerieux: Filmarray Torch is FDA cleared

* Filmarray Torch is now FDA cleared with all 4 existing Filmarray panels and the system gets CE marked Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 08 2016

BRIEF-Biomerieux and Copan announce the first commercial success of their collaboration

* Biomerieux and Copan announce the first commercial success of their collaboration for the automation and efficiency of microbiology laboratories Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Mar 22 2016

BRIEF-Biomerieux FY consolidated income down 18.5 pct at 110 mln euros

* Reports FY consolidated net income of 110 million euros ($119.5 million) versus 136 million euros a year ago

Mar 02 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Sadif Analytics Prime
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.